Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 24, 2024 08:01 ET
|
Intellia Therapeutics, Inc.
Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16,...
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
October 07, 2024 07:30 ET
|
Intellia Therapeutics, Inc.
NTLA-2002 is a single-dose treatment designed to prevent potentially life-threatening swelling attacks in people with hereditary angioedema (HAE)NTLA-2002 is Intellia’s second in vivo candidate to...
Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)
March 02, 2023 07:00 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies...
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
September 16, 2022 07:00 ET
|
Intellia Therapeutics, Inc.
Positive interim clinical data further validate the modularity of Intellia’s industry-leading genome editing platform and its potential to target a multitude of genetic diseases A single dose of...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
December 13, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...
BioCryst Adds $350 Million in New Financing with Royalty Pharma and OMERS Capital Markets
November 22, 2021 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Provides funding for BCX9930/oral Factor D program across multiple indications— —Agreements supported by strength of ORLADEYO® (berotralstat) launch and confidence in future opportunity— NEW YORK,...
Intellia Therapeutics Announces First Quarter 2021 Financial Results
May 06, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
Plan to report initial safety and activity data from Phase 1 study of NTLA-2001, a potentially curative single-dose therapy for transthyretin amyloidosis (ATTR), in mid-2021 On track to submit an IND...
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
May 06, 2020 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
—Berotralstat approval/launch timelines in U.S., Japan, EU remain on track— —Early clinical data supports BCX9930 as oral monotherapy for complement-mediated diseases— —Patient dosing underway in...
BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors
November 20, 2018 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 20, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed Theresa Heggie to its Board of Directors. ...
BioCryst Reports Third Quarter 2018 Financial Results
November 06, 2018 07:00 ET
|
BioCryst Pharmaceuticals, Inc.
APeX-2 study enrollment completed, results on-track for Q2 2019 RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced...